Wall Street Closes Out Strong Quarter as Investors Weigh Lilly's Mixed Obesity Drug Data

Wall Street closed out a strong quarter of trading, even as investors digested mixed data from a clinical trial of Eli Lilly's obesity drug that added a note of uncertainty to the broader market picture.

The quarter's gains reflect sustained momentum in equities heading into the final stretch of trading, though individual stock moves, including Lilly's, showed that not every sector shared equally in the advance.

Lilly's trial data

Eli Lilly's latest obesity drug trial results were described as mixed, suggesting the data included both encouraging and less favorable findings that left analysts without a clear-cut verdict on the treatment's prospects.

The mixed results come at a time of intense investor interest in obesity drugs, a category that has drawn significant attention and capital across the pharmaceutical sector in recent periods.

Further clarity on how the trial data will affect Lilly's stock and broader sentiment toward obesity treatments is expected as analysts continue to review the full results.